Portopulmonary hypertension

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with portal hypertension. Pulmonary hypertension in patients with liver disease or portal hypertension can be due to multiple mechanisms, including hyperdynamic (high-flow) state, increased pulmonary venous congestion, and vascular constriction or obstruction of the pulmonary arterial bed. Vascular obstruction to pulmonary arterial flow, reflected by increased pulmonary vascular resistance (PVR), is a key parameter that defines POPH. Among patients with portal hypertension, reported incidence rates of POPH range from 2 to 9%. Long-term survival in cases of POPH is poor. Favorable responses to pulmonary vasodilator/vasomodulatory therapy have been observed, but prospective, randomized trials are lacking. Severe POPH with right ventricular failure despite vasodilator therapy is associated with poor outcomes in the setting of liver transplantation (LT) and is considered a contraindication to LT. The post-LT course of patients with moderate POPH is unpredictable, but most patients can be weaned from PAH-specific therapy over time.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalSeminars in Respiratory and Critical Care Medicine
Volume33
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Hypertension
Portal Hypertension
Pulmonary Hypertension
Liver Transplantation
Lung
Vasodilator Agents
Blood Vessels
Hyperemia
Constriction
Vascular Resistance
Liver Diseases
Therapeutics
Survival
Incidence

Keywords

  • liver transplant
  • portal hypertension
  • portopulmonary hypertension
  • pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Portopulmonary hypertension. / Krowka, Michael Joseph.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 33, No. 1, 2012, p. 17-25.

Research output: Contribution to journalArticle

@article{6b4233569cad4d94a83e9ada999b5b9c,
title = "Portopulmonary hypertension",
abstract = "Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with portal hypertension. Pulmonary hypertension in patients with liver disease or portal hypertension can be due to multiple mechanisms, including hyperdynamic (high-flow) state, increased pulmonary venous congestion, and vascular constriction or obstruction of the pulmonary arterial bed. Vascular obstruction to pulmonary arterial flow, reflected by increased pulmonary vascular resistance (PVR), is a key parameter that defines POPH. Among patients with portal hypertension, reported incidence rates of POPH range from 2 to 9{\%}. Long-term survival in cases of POPH is poor. Favorable responses to pulmonary vasodilator/vasomodulatory therapy have been observed, but prospective, randomized trials are lacking. Severe POPH with right ventricular failure despite vasodilator therapy is associated with poor outcomes in the setting of liver transplantation (LT) and is considered a contraindication to LT. The post-LT course of patients with moderate POPH is unpredictable, but most patients can be weaned from PAH-specific therapy over time.",
keywords = "liver transplant, portal hypertension, portopulmonary hypertension, pulmonary hypertension",
author = "Krowka, {Michael Joseph}",
year = "2012",
doi = "10.1055/s-0032-1301731",
language = "English (US)",
volume = "33",
pages = "17--25",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Portopulmonary hypertension

AU - Krowka, Michael Joseph

PY - 2012

Y1 - 2012

N2 - Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with portal hypertension. Pulmonary hypertension in patients with liver disease or portal hypertension can be due to multiple mechanisms, including hyperdynamic (high-flow) state, increased pulmonary venous congestion, and vascular constriction or obstruction of the pulmonary arterial bed. Vascular obstruction to pulmonary arterial flow, reflected by increased pulmonary vascular resistance (PVR), is a key parameter that defines POPH. Among patients with portal hypertension, reported incidence rates of POPH range from 2 to 9%. Long-term survival in cases of POPH is poor. Favorable responses to pulmonary vasodilator/vasomodulatory therapy have been observed, but prospective, randomized trials are lacking. Severe POPH with right ventricular failure despite vasodilator therapy is associated with poor outcomes in the setting of liver transplantation (LT) and is considered a contraindication to LT. The post-LT course of patients with moderate POPH is unpredictable, but most patients can be weaned from PAH-specific therapy over time.

AB - Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with portal hypertension. Pulmonary hypertension in patients with liver disease or portal hypertension can be due to multiple mechanisms, including hyperdynamic (high-flow) state, increased pulmonary venous congestion, and vascular constriction or obstruction of the pulmonary arterial bed. Vascular obstruction to pulmonary arterial flow, reflected by increased pulmonary vascular resistance (PVR), is a key parameter that defines POPH. Among patients with portal hypertension, reported incidence rates of POPH range from 2 to 9%. Long-term survival in cases of POPH is poor. Favorable responses to pulmonary vasodilator/vasomodulatory therapy have been observed, but prospective, randomized trials are lacking. Severe POPH with right ventricular failure despite vasodilator therapy is associated with poor outcomes in the setting of liver transplantation (LT) and is considered a contraindication to LT. The post-LT course of patients with moderate POPH is unpredictable, but most patients can be weaned from PAH-specific therapy over time.

KW - liver transplant

KW - portal hypertension

KW - portopulmonary hypertension

KW - pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84858740438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858740438&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1301731

DO - 10.1055/s-0032-1301731

M3 - Article

C2 - 22447257

AN - SCOPUS:84858740438

VL - 33

SP - 17

EP - 25

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 1

ER -